Behandlung von Zwangsstörungen

Abstract

1. Jelinek L, Moritz S, Miegel F et al. Obsessivecompulsive disorder during COVID-19: Turning a problem into an opportunity? Journal of Anxiety Disorders 2021;77:102329 2. Asmundson GJ, Paluszek MM, Landry CA et al. Do pre-existing anxiety-related and mood disorders differentially impact COVID-19 stress responses and coping? Journal of Anxiety Disorders 2020;74:102271 3. Schlegl S, Maier J, Meule A et al. Eating disorders in times of the COVID‐19 pandemic— Results from an online survey of patients with anorexia nervosa. International Journal of Eating Disorders 2020a;53(11):17911800 4. Schlegl S, Meule A, Favreau M et al. Bulimia nervosa in times of the COVID‐19 pandemic—Results from an online survey of former inpatients. European Eating Disorders Review 2020b;28(6):847-54 5. Pérez-Vigil A, de la Cruz LF, Brander G, Isomura K, Jangmo A, Feldman I, et al. Association of Obsessive-Compulsive Disorder with Objective Indicators of educational attainment: a Nationwide register-based sibling control study. JAMA Psychiatry 2018;75(1):47-55 6. Schneider SC, Knott L, Cepeda SL et al. Serious negative consequences associated with exposure and response prevention for obsessive‐compulsive disorder: A survey of therapist attitudes and experiences. Depression and Anxiety 2020;37(5):418-28 7. Launes G, Hagen K, Sunde T et al. A randomized controlled trial of concentrated ERP, self-help and waiting list for obsessivecompulsive disorder: The Bergen 4-Day Treatment. Frontiers in Psychology 2019;10:2500 8. Launes G, Hagen K, Öst LG et al. The Bergen 4-Day Treatment (B4DT) for ObsessiveCompulsive Disorder: Outcomes for Patients Treated After Initial Waiting List or SelfHelp Intervention. Frontiers in Psychology 2020;11:982 9. Xu J, Liu RJ, Fahey S, Frick L et al. Antibodies from children with PANDAS bind specifically to striatal cholinergic interneurons and alter their activity. American Journal of Psychiatry 2021;178(1):48-64 10. Mataix-Cols D, Frans E, Pérez-Vigil A et al. A total-population multigenerational family clustering study of autoimmune diseases in obsessive–compulsive disorder and Tourette’s/chronic tic disorders. Molecular Psychiatry 2018;23(7):1652-8 11. Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. The Journal of Clinical Psychiatry 2006;67(1):15-22 12. Koran LM, Hanna GL, Hollander E et al. Practice guideline for the treatment of patients with obsessive-compulsive disorder: Arlington, VA: American Psychiatric Association; 2007 13. Kayser RR, Raskin M, Snorrason I et al. Cannabinoid Augmentation of Exposure-Based Psychotherapy for Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology 2020a;40(2):207-10 14. Kayser RR, Haney M, Raskin M et al. Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study. Depression and Anxiety 2020b;37(8):801-11 15. Hageman SB, van Rooijen G, Bergfeld IO et al. Deep brain stimulation versus ablative surgery for treatment‐refractory obsessive‐ compulsive disorder: A meta‐analysis. Acta Psychiatrica Scandinavica 2021;143(4):30718 Fortbildung